SCHEMBL1471735

SCHEMBL1471735

O=C1C=C(c2ccccc2)C(=O)N1c1cccc(Br)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.56
ALDH1A1 P00352 7/20 0.46
MAPT P10636 4/20 0.46
GAA P10253 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
CCR6 P51684 2/20 0.46
HPGD P15428 2/20 0.46
ALOX12 P18054 2/20 0.46
CACNA1B Q00975 2/20 0.46
APBA1 Q02410 2/20 0.46
ATM Q13315 2/20 0.46
HTT P42858 2/20 0.46
HSP90AA1 P07900 2/20 0.46
FAAH O00519 2/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
DCTPP1 Q9H773 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471293 0.87 ALDH1A1 (0.49) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL1473671 0.87 MGLL (0.51) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL1473707 0.85 MGLL (0.47) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL303331 0.85 ALDH1A1 (0.51) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL934144 0.84 MGLL (0.53) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL1471789 0.83 MGLL (0.54) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL1471130 0.83 MGLL (0.54) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL28976664 0.83 ALDH1A1 (0.45) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL30272745 0.83 ALDH1A1 (0.45) MGLLALDH1A1MAPTGAANPSR1
SCHEMBL1471845 0.83 HSP90AA1 (0.54) MGLLALDH1A1MAPTGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US claimed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP claimed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US claimed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP claimed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO claimed
WO-2016144352-A2 THERAPEUTIC COMPOSITIONS INCLUDING ACRYLAMIDO COMPOUNDS OR PHENYL-SUBSTITUTED MALEIMIDE COMPOUNDS, VARIANTS THEREOF AND METHODS OF USING THE SAME STEALTH PEPTIDES INTERNATIONAL, INC. (MC) 2016-09-15 WO disclosed
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885ALDH1A1 800/4885MAPT 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.